Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Dasman Diabetes Institute
1 Jan 1990 → …
Fingerprint
Dive into the research topics where Thamer AlEssa is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
Improving glucose control of poorly controlled insulin treated T2DM patients in Kuwait
Al-Mulla, F. (PI), Abdulghani, M. (PI), Alajmi, F. (CoI), Abu-Farha, M. (CoI), AlEssa, T. (CoI), Al-Otaibi, N. (CoI), Shehab, M. (CoI) & Ahmed, M. (CoI)
1/05/24 → 1/05/29
Project: Dasman Diabetes Institute Projects
-
Phase 2: Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Al-Mulla, F. (PI), Abdul-Ghani, M. (PI), Abu-Farha, M. (CoI), Al-Ajmi, F. (CoI), AlEssa, T. (CoI), Khalifa, D. (CoI), Abubaker, J. (CoI) & Devarajan, S. (CoI)
1/03/24 → 1/06/26
Project: Dasman Diabetes Institute Projects
Research output
- 11 Article
-
Al-Mulla, F., Abu-Farha, M., Alajmi, F., Abubaker, J., Ahmed, M., Qaddoumi, M., Shehab, M., Mclaws, A. J., Alessa, T., Alhubail, A., Alsaeed, D., Arouj, M., Bennakhi, A., DeFronzo, R., & Abdulghani, M. (2024). one-hour plasma glucose concentration during the ogtt is a strong predictor of hepatic steatosis in nondiabetic individuals. Diabetologia, 67, S451-S451.
-
DeFronzo, R., Abdul-Ghani, M., Baskoy, G., Nakhleh, A., Abdelgani, S., Al-Mulla, F., Abu-Farha, M., Alajmi, F., Alessa, T., & Shehadeh, N. (2024). pioglitazone amplifies the decrease in hba1c and prevents the increase in plasma ketone caused by dapagliflozin in type 1 diabetes patients. Diabetologia, 67, S60-S61.
-
Aljumah, M., Abufarha, M., Alyassen, H., Alessa, T., Devarajan, S., & Nabil, M. (2023). maternal and neonatal morbidity and mortality among covid-19 positive pregnant women with and without gdm. Diabetes Research and Clinical Practice, 197. https://doi.org/10.1016/j.diabres.2023.110416
-
Baagar, K., Alessa, T., Jayyousi, A., Ceruto, J., Alattar, A., Hamad, M., Almatrouk, H., Abdulrahman, S., Alhumaidi, H., Alandaleeb, A., Esmaeel, A., Abu-Farha, M., Al-Mulla, F., & Abdul-Ghani, M. (2023). pioglitazone for patients with type 2 diabetes admitted with covid-19 infection. Diabetologia, 66(SUPPL 1), S176-S176.
-
Abu-Farha, M., Al-Khairi, I., Qaddoumi, M., Al-Sabah, S., AlSabbagh, A., Lopez, V., Alessa, T., Kumar, J., Abukhalaf, N., Cherian, P., Al-Mulla, F., Abubaker, J., & Abdul-Ghani, M. (2023). synergistic effects of tirzepatide and pioglitazone on insulin sensitivity and beta cell function in diet-induced obese rats. Diabetologia, 66(SUPPL 1), S26-S26.